# Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices

> **NCT05626777** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 20 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Pre-filled syringe, mepolizumab 100 mg/month
- **DRUG:** Auto-injector pen, mepolizumab 100 mg/month

## Key facts

- **NCT ID:** NCT05626777
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-09
- **Primary completion:** 2026-03
- **Final completion:** 2026-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05626777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05626777, "Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05626777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*